FDA Withdraws Two Guidances on Estrogen and Hormone Replacement Therapy

Summary

The Food and Drug Administration (FDA) is withdrawing two guidances related to estrogen and hormone replacement therapy for postmenopausal women, including a labeling guidance and a clinical evaluation guidance, which are currently under review for changes.